VERRICA PHARMACEUTICAL

Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition

05 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services

29 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts

04 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™

03 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan

15 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

09 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

25 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

24 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

23 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting

10 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

08 Aug 2023 06:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting

03 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

26 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

21 Jul 2023 15:24:31 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

31 May 2023 06:00:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

10 May 2023 06:30:00 By Nasdaq GlobeNewswire